Geron Corporation · NASDAQ:GERN
Geron — Investor Presentation (January 2021)
31 slides from Geron's investor presentation, Jan 8, 2021
Slide 1: Changing the course of hematologic malignancies
geron Changing the course of hematologic malignancies Corporate Presentation
Slide 2: Forward-Looking Statements
Forward-Looking Statements Except for the historical information contained herein, this presentation contains forward-looking statements made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements
Slide 3: Geron's Vision Being Realized
Geron’s Vision Being Realized Changing the course of hematologic malignancies by targeting telomerase wont with imetelstat 2022-2024 Top-tine results for 2020-2021 Phase 3LR MDS Strong evidence from expected 2019-2020 Phase 2fordisease 2H2022 eae ‘modification 2017-2019 ete” ImprovementinOS (MF) _Im
Slide 4: Geron's Vision Being Realized
Geron’s Vision Being Realized Our Mission To Improve and Extend Patient Lives by Changing the Course of Hematologic Malignancies by Targeting Tel geron merase Imetelstat in LR MDS and MF + Imetelstat MOA provides highly differentiated product profile *+ Evidence for disease modi tion has continued t
Slide 5: Changing the course of hematologic malignancies by targeting telomerase with imetelstat
geron Changing the course of hematologic malignancies by targeting telomerase with imetelstat
Slide 6: Hematologic Myeloid Malignancies
Hematologic Myeloid Malignancies Ai geron ise from mali nant cells with continuously upregulated telomerase ‘imonBOCrTHEMIA ET) trorma RS #9 yeooyseuasric ‘SYMDROMES (wDS) oe raqrerhemn vera tEUKENIA irra = ov we These disorders are caused by uncontrolled proliferation of malignant stem and progenit
Slide 7: Imetelstat Impact
Imetelstat Impact Inhibiting uncontrolled proliferation of malignant cells by targeting telomerase Imetelstat is a competitive telomerase inhibitor developed and 100% owned by Geron; no 3" party IP obligations inducing their apoptosis (cell death), and enabling potential recovery of normal hematopoi
Slide 8: Transformative Potential of Imetelstat
Transformative Potential of Imetelstat Changing the course of hematologic malignancies Normalization of platelet THiwOMBOCYTHEMIA — pg rcrrier oes (oreo MYELODYSPLASTIC = mutation burden SYNDROMES(Mos) _| Durable transfusion independence; ieee estes Depletion of cytogenetic KX abnormalities and muta
Slide 9: Changing the course of lower risk MDS (LR MDS)
geron Changing the course of lower risk MDS (LR MDS)
Slide 10: Lower Risk Myelodysplastic Syndromes (LR MDS)
Lower Risk Myelodysplastic Syndromes (LR MDS) Imetelstat to address significant unmet need with a large market opportunity Disease Characteristics * Malignant stem and progenitor cells in the bone marrow lead to ineffective production of RBCs, WBCs, and platelets (hematopoiesis) * Primary clinical p
Slide 11: IMerge Phase 2 Clinical Trial
IMerge Phase 2 Clinical Trial Key Efficacy and Safety Results Clinicaria gov (werozsssse1) Meaning and Durable Transfusion Independence (TI) Low or Intermediate-1 risk MDS Non-del(5q) ee > 8-week TI: 42% ‘Transfusion Dependent Relapsed/refractory to ESAS é > 24-week Tl: 32% (n=38) = . Duration of TI
Slide 12: Key Imetelstat Efficacy Results in LR MDS
Key Imetelstat Efficacy Results in LR MDS Breadth (RS+/RS-), depth (RB | Rate) and durabili of response IMerge Phase 2 Imetelstat Luspatercept Placebo = No.of patients 13 76 Non-del(Sq) R/RtO ESAS ‘Target patient population Non-del(Sq) R/RtO ESAS RS+ and RS- (MDS ring sideroblast (RS) subgroups. RS+
Slide 13: Phase 2 IMerge Results: Disease-Modifying Activity Evidence
Phase 2 IMerge Results: Disease-Modifying Activity Evidence Reductions in key MDS mutation correlate with higher rate and durability of transfusion independence Imetelstat led to SF3B1 VAF reductions 8-wk TI responders had greater reduction of SF3B1 VAF Percent SF3B1 VAF Reduction vs compared to 8-w
Slide 14: Imetelstat in LR MDS
Imetelstat in LR MDS* Highly differentiated therapy designed to address current unmet need High Rates of Transfusion Independence (TI) 42% of patients achieved 8-week TI and 68% achieved hematologic improvement (HI-E) Durability of Transfusion Independence 29% of patients were transfusion free for>1
Slide 15: IMerge Phase 3 Clinical Trial Enrolling
IMerge Phase 3 Clinical Trial Enrolling Imetelstat Low or Intermediate-1 risk MDS 7.5mg/kg every 4 weeks Non-del(5q) (n~115) Transfusion Dependent Relapsed/refractory to ESAs (n=170) Similar to Phase 2 Trial with Placebo Arm Added + Same target population, including both RS+ and RS- patient groups +
Slide 16: Changing the course of MF
geron Changing the course of MF
Slide 17: Int-2/High-Risk Myelofibrosis
Int-2/High-Risk Myelofibrosis Imetelstat to address significant unmet need with a large market opportunity Disease Characteristics * Malignant stem and progenitor cell proliferation give rise to malignant megakaryocytes, bone marrow fibrosis and impaired hematopoie: * Splenomegaly: normal blood prod
Slide 18: IMbark Phase 2 Clinical Trial
IMbark Phase 2 Clinical Trial IMbark CinciatTias gov (were2s26086} Imetelstat Co-primary endpoints: Spleen response rate and symptom response rate Intermediate-2 or “ = sige High-Risk MF ey secondary endpoints: CR, PR, Cl and anemia response per 2013 IWG-MRT Relapsed/refractory to criteria; overall
Slide 19: IMbark Phase 2 Efficacy Results
IMbark Phase 2 Efficacy Results Dose-dependent impact on OS, reduction in fibrosis and reduction in driver disease mutations 4.7 mg/kg, mg/kg Clinical Benefits (N=48) (N=59) Median OS, months (95% Cl) 19.9 (17.1, 33.9) 28.4 (22.8, 31.6) Reduction in bone marrow fibrosis , n/N (%) 4/20 (20.0%) 16/37(
Slide 20: IMbark Phase 2 Efficacy Results
IMbark Phase 2 Efficacy Results IMbark Phase 2 Data: Imetelstat 4.7 vs. 9.4 mg/kg RWD BAT vs. Imetelstat 9.4 mg/kg ad aptn-teier Cues (Unweiglos ot Nae Companson ‘Survival prbebity Sin poet Number atk H wrasse 7 2 2 % 8 2 a tt Improvement in Overall Survival * 28 mos median OS in Int-2/High-risk R/R
Slide 21: IMbark Phase 2 Efficacy Results
IMbark Phase 2 Efficacy Results Mba Clinciaftiake gov Improved OS in poor prognosis triple-negative (TN) and high molecular risk (HMR) patients (ncro2s26086) ess SS SS SSS Improved survival in TN MF patients treated with 9.4 mg/kg imetelstat Improved survival in HMR patient treated with 9.4 mg/kg im
Slide 22: IMbark Phase 2 Results: Disease-Modifying Activity Evidence
IMbark Phase 2 Results: Disease-Modifying Activity Evidence Dose-dependent reduction in key MF driver mutations correlate with clinical outcomes Dose-dependent reduction in key MF driver mutations 106 2” Re soos} ny aK Jo i gm ‘a a = ‘povot3 4005 Dares Ba.e/e Higher spleen and symptom response and f
Slide 23: IMbark Phase 2 Results: Disease-Modifying Activity Evidence
IMbark Phase 2 Results: Disease-Modifying Activity Evidence Improved bone marrow fibrosis correlates with improved survival * Dose related improvement in bone marrow fibrosis * Patients with bone marrow fibrosis stable or improvement had lower risk of death than those who. had worsening bone marrow
Slide 24: Imetelstat in Int-2/High-Risk Myelofibrosis
Imetelstat in Int-2/High-Risk Myelofibrosis” Highly differentiated therapy designed to address current unmet need Improvement in Overall Survival relapsed/refractory to JAKi compares favorably to triple negative and HMR patients historical controls of 14-16 mos. and 12 mos. from RWD analyses of best
Slide 25: IMpactMF Open for Enrollment
IMpactMF Open for Enrollment rst and only Phase 3 tria MF with OS as endpoint Imetelstat Renee een lo.4 mg/kg every 3 weeks Primary endpoint: High-Risk MF (n-214) Overall survival (OS) Refractory to Key secondary endpoints: JAK inhibitors (JAKi)* Teeny my Excluding JAKi (n~106) * Defined as-inadequa
Slide 26: Transition to commercial-stage company
geron Transition to commercial-stage company
Slide 27: NDA/MAA Readiness Plans for Imetelstat in Lower Risk MDS
NDA/MAA Readiness Plans for Imetelstat in Lower Risk MDS 2023" Regulatory Clearance of 2H 2022* IMerge Trial Design 2021: outline contents; commence drafting; implement e-filing systems 2022: finalize nonclinical and CMC content; conduct pre-NDA/MAA meetings with health authorities US & EU Orphan Dr
Slide 28: Stage-Gated Commercial Enterprise Build
Stage-Gated Commercial Enterprise Build egrated U.S. Commercial Organi Established 2021 Launch Imperatives 1. Prepare the Product 2. Prepare the Market US. Commercial 3, Prepare the Organization Team Expansion Execute US “go-to-market” strategy Establish Commercial Leadership (Access, Medical Affair
Slide 29: Geron's Vision Being Realized
Geron’s Vision Being Realized Our Mission To Improve and Extend Patient Lives by Changing the Course of Hematologic Malignancies by Targeting Tel geron merase Imetelstat in LR MDS and MF + Imetelstat MOA provides highly differentiated product profile *+ Evidence for disease modi tion has continued t
Slide 30: For questions, please email investor@geron.com
geron For questions, please email investor@geron.com Geron Corporation (Nasdaq: GERN) 30
Slide 31: References
References geron slide © Steensma etal, JCO2021 + EHA2020:Platabecker U, etal + EHA2020: Mascarenhas J et al + ASH2020: Mascarenhas J, etal + EHA2019:KuykendallA, etal ‘+ ASH 2016: Mascarenhas J, etal slides © Steenema.t al, JCO2021 + ASH2020: Mascarenhas, etal slides + Briatore, etal. Cancer Biol T